These include focused libraries of small-molecule compounds with potential biological activity towards certain diseases (such as Anti-Cancer Compound Library, Anti-Diabetic Compound Library, Anti-Cardiovascular Disease Compound Library, etc.).
Cat No. | product name | ||
---|---|---|---|
L2100 | Anti-cancer Compound Library | A unique collection of 4412 compounds with anti-cancer activity for high throughput screening (HTS) and high content screening (HCS); | 4412 compounds |
L1900 | Anti-diabetic Compound Library | A unique collection of 179 diabetes related compounds; | 179 compounds |
L1800 | Anti-infection Compound Library | A unique collection of 605 anti-infective compounds including anti-bacterial, anti-fungi, anti-Human Cytomegalovirus (HCMV), anti-HIV, anti-SARS, anti-influenza, etc; | 605 compounds |
L1700 | Anti-virus Compound Library | Quantity: A unique collection of 526 anti-virus compounds effective for new anti-virus drugs high throughput screening and high content screening; | 526 compounds |
L4700 | Immunology/Inflammation Compound Library | A unique collection of 2682 anti-inflammation compounds effective for high throughput screening and high content screening. | 2682 compounds |
L4500 | Antifungal Compound Library | A unique collection of 66 antifungal compounds effective for drug repurposing screening, combination screening and biological investigation. | 66 compounds |
L2110 | Anti-cancer Approved drug Library | A unique collection of 388 approved anti-cancer drugs for high throughput screening (HTS) and high content screening (HCS); | 388 compounds |
L2120 | Anti-cancer Clinical Compound Library | A unique collection of 688 anti-cancer compounds for high throughput screening (HTS) and high content screening (HCS); | 688 compounds |
L5200 | Anti-Metabolism Disease Compound Library | A unique collection of 1040 metabolism diseases related compounds for high throughput screening (HTS) and high content screening (HCS); | 1040 compounds |
L5400 | Anti-Cardiovascular Disease Compound Library | A unique collection of 515 cardiovascular diseases related compounds for high throughput screening (HTS) and high content screening (HCS); | 515 compounds |
L2130 | Anti-cancer Metabolism Compound Library | A unique collection of 237 cancer cellular metabolism related compounds for cancer research and high throughput screening (HTS) and high content screening (HCS); | 237 compounds |
L2140 | Promoting Cancer Cell Differentiation Compound Library | A unique collection of 251 cancer cell differentiation inducing compounds for high throughput and high content screening; | 251 compounds |
L7100 | Anti-obesity Compound Library | A unique collection of 755 anti-obesity compounds for high throughput and high content screening; | 755 compounds |
L8400 | Hematonosis Compound Library | A unique collection of 126 compounds related to hematologic diseases for high throughput screening (HTS) and high content screening (HCS); | 126 compounds |
L2160 | Anti-cancer Active Compound library | A unique collection of 1399 compounds with known anti-cancer activity for high throughput screening (HTS) and high content screening (HCS); | 1399 compounds |
L2150 | Anti-cancer Drug library | A unique collection of 822 anticancer drugs for high throughput screening (HTS) and high content screening (HCS); | 838 compounds |
L4510 | Anti-Parasite Library | Quantity: 358 well-chosen unique anti-parasitic small molecules; | 358 compounds |
L4520 | Antibacterial Activity Library | A unique collection of 909 antibacterial bioactive compounds, a powerful tool for antibacterial drug development; | 909 compounds |
L4660 | Nervous system disease Library | Quantity: well-chosen 935 compounds with unique structures targeting nervous system; | 935 compounds |
L2180 | Anticancer Library Plus | Quantity: well-chosen 958 anti-tumor compounds with unique structures; | 958 compounds |
L2170 | Small Molecule Immuno-Oncology Compound Library | A unique collection of 235 compounds acting on immune-oncology therapeutic targets can be used for high throughput and high content screening; | 235 compounds |
L1710 | Anti-COVID-19 Compound Library | A unique collection of 2448 compounds with confirmed anti-SARS-CoV-2 activity or potential activity and part of them are broad-spectrum antiviral agents; | 2448 compounds |
L1711 | Anti-COVID-19 compound library (CADD) | A unique collection of 362 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening; | 362 compounds |
L1712 | 3CLpro-Targeted compound library (CADD) | A unique collection of 161 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening; | 161 compounds |
L1713 | ACE2-Targeted compound library (CADD) | A unique collection of 462 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening; | 462 compounds |
L1714 | RBD-Targeted compound library (CADD) | A unique collection of 206 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening; | 206 compounds |
L1715 | nsp16-Targeted compound library (CADD) | A unique collection of 281 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening; | 281 compounds |
L1716 | PLpro-Targeted compound library (CADD) | A unique collection of 474 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening; | 474 compounds |
L1717 | RdRP-Targeted compound library (CADD) | A unique collection of 464 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening; | 464 compounds |
L1718 | X Domain-Targeted compound library (CADD) | A unique collection of 463 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening; | 463 compounds |
L1719 | nsp15-Targeted compound library (CADD) | A unique collection of 470 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening; | 470 compounds |
L2620 | Neurodegenerative disease-related Compound Library | A unique collection of 902 compounds related to neurodegenerative diseases can be used for HTS or HCS; | 902 compounds |
L2190 | Anti-Lung Cancer Compound Library | A unique collection of 400 compounds with anti-lung cancer therapeutic activity or targeting lung cancer’s major signaling pathways, can be used for anti-lung cancer drug discovery and mechanism study; | 400 compounds |
L4710 | Nonsteroidal Antiinflammatory Compound Library | 530 non-steroidal anti-inflammatory compounds for high-throughput and high-content screening. | 530 compounds |
L2191 | Anti-Breast Cancer Compound Library | ||
L2192 | Anti-Pancreatic Cancer Compound Library | 788 compounds | |
DD4000 | Antiviral Annotated Library | 22775 compounds | |
DD5100 | CNS Annotated Library | 733 compounds | |
DD5500 | Opportunistic Pathogens of Immunocompromised Hosts Annotated Library | 2100 compounds | |
T002-00000003 | Anti-Parkinson's Disease Compound Library | 184 compounds | |
T002-00000002 | Anti-Alzheimer's Disease Compound Library | 623 compounds |